GLP-1s and Low Blood Sugar While Fasting: Who's Actually at Risk

Hypoglycemia — low blood sugar — is uncommon with a GLP-1 medication used by itself, because these drugs raise insulin mainly when blood glucose is already high. That glucose-dependent action is the key: as your sugar falls toward normal, the drug's insulin push eases off. The picture changes when a GLP-1 is combined with other glucose-lowering medications, and a fasting window can tip it further. Here's who needs to pay attention.

Why a GLP-1 alone is low-risk

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) stimulate insulin release primarily in response to elevated blood sugar. Unlike older drugs that push insulin regardless of your glucose level, they largely leave you alone once you're in the normal range. For someone taking a GLP-1 as their only glucose-lowering medication, the risk of a dangerous low — even while fasting — is small.

The real risk: insulin and sulfonylureas

The combination that matters is a GLP-1 plus insulin or an insulin secretagogue — the sulfonylurea class: glipizide, glimepiride, glyburide. These drugs lower blood sugar whether or not you've eaten, so stacking them with the appetite loss of a GLP-1 and the food gap of a fast is what creates real hypoglycemia risk.

The drug labels are direct about it. For semaglutide, the FDA advises considering a dose reduction of insulin or a sulfonylurea to reduce hypoglycemia risk. For tirzepatide, the effect is quantified: severe-range lows (under 54 mg/dL) occurred in about 4% of people on the weight-loss dose, but rose to roughly 10% among those also taking a sulfonylurea, versus about 2% without one. Both Mounjaro and Zepbound labels advise reducing the insulin or sulfonylurea dose at initiation.

Do not adjust your own insulin or sulfonylurea dose to "make room" for fasting. That's a change to make with the clinician who prescribes them — often alongside a plan to check your glucose more closely at first.

How fasting adds to it

A fasting window removes the incoming glucose your medication was partly timed around. If your insulin or sulfonylurea dose was set for your usual eating pattern, extending the gap between meals can leave that dose "unopposed" — the classic setup for a low. This is why the safe sequence is adjust medications first, then fast — never the reverse.

Know the warning signs

Early hypoglycemia can feel like: shakiness, sweating, a racing heart, sudden hunger, irritability, or trouble concentrating. Left unchecked it can progress to confusion, slurred speech, or fainting — a medical emergency.

If you feel a low coming on and can test, the standard response is the 15–15 rule: take about 15 grams of fast-acting carbohydrate (glucose tablets, 4 oz of juice or regular soda), wait 15 minutes, and re-check. Repeat if you're still low. If someone can't safely swallow or loses consciousness, it's a 911 situation.

Who should be most careful

Treat fasting as a "clinician-first" decision if you:

• take insulin or a sulfonylurea with your GLP-1,
• have type 1 diabetes,
• live alone and wouldn't be found quickly during a severe low,
• have had hypoglycemia before, or reduced awareness of it,
• or are pregnant or breastfeeding.

If a GLP-1 is your only glucose-lowering drug and you're otherwise well, gentle fasting is generally low-risk — but the practical cautions in our fasting-on-a-GLP-1 guide still apply, and starting with a gentle window on Ozempic or tirzepatide is the right pace.

This article is educational, not medical advice. Never change an insulin or sulfonylurea dose on your own — that decision belongs with your prescriber.